Strand Therapeutics

#mRNA #Oncology #Phase I trial #Strand Therapeutics

First patients receive mRNA therapy for tumour-selective activation

Strand Therapeutics has dosed the first patients in its ASCENT-1 Phase I clinical trial of STX-003, an intravenously delivered self-replicating mRNA therapy designed to selectively express IL-12 within tumours while restricting expression in healthy tissue.   This is the first clinical evaluation of Strand’s SignalLock genetic circuitry, designed… Read More

#Cancer Research #News

Business financing
#Financing #mRNA #Oncology #Strand Therapeutics

Strand Therapeutics raises $153 million for mRNA therapies

Strand Therapeutics has announced a $153 million Series B funding led by Kinnevik, with new investors including Regeneron Ventures, ICONIQ, and Amgen Ventures.  The funding will advance Strand’s pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumour microenvironment. … Read More

#Business & Investment #News

RNA
#Business #FDA #mRNA #Oncology #Strand Therapeutics

Strand Therapeutics cuts workforce by 18%

Strand Therapeutics has announced an 18% cut to its workforce, just days after the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to initiate a first-in-human trial of STX-001 for solid tumours. On LinkedIn the company said: “This week, Strand has… Read More

#Business & Investment #News #Trending News

RNA
#Clarivate #HAYA Therapeutics #Immunotherapy #mRNA #RNA #RNA sequencing #Strand Therapeutics

RNA companies to watch over the next 12 months

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment.  Therapies that act upon or incorporate RNA to fight disease have… Read More

#Exclusive Content #Market Reports